# Claim table — NeuralCIM / NeuroEPO Alzheimer’s YouTube source-check

| Video claim / issue | Evidence label | What the source trail supports |
|---|---|---|
| NeuralCIM / NeuroEPO plus is derived from erythropoietin and is delivered intranasally. | Supported by trial/publication descriptions. | ATHENEA describes recombinant human erythropoietin with low sialic acid content, administered intranasally. |
| A Cuban randomized trial showed improvement or stability in many mild-to-moderate Alzheimer’s participants. | Supported, with caution. | ATHENEA enrolled 174 / treated 170 participants; ADAS-Cog11 improved in treatment arms while placebo worsened at 48 weeks. Authors call for larger trials. |
| The video’s “84% improved or stable” summary proves a world-changing cure. | Overstated. | The trial signal is notable, but one Cuban multicenter trial plus follow-up does not establish broad global effectiveness, durability, access, or regulatory approval outside Cuba. |
| No major safety problems were observed. | Supported within reported trial limits. | ATHENEA reported no treatment-related serious adverse events, but larger/independent studies are still needed. |
| U.S./Canadian patients can simply get this treatment. | Access-limited / not verified. | Cuba has approved the drug; a University of Saskatchewan Phase 2 trial is registered but not yet recruiting in the recovered ClinicalTrials.gov record. FDA/Health Canada approval was not verified. |
| The story is relevant to PBC Health. | Yes. | It is a medical-access, sanctions, trial-evidence and patient-choice story; publish with strict medical caveats. |
| Judge/court extraction needed. | No. | No court/judge component was identified. |

| The people and film story proves the treatment works globally. | No — context only. | Teresita’s Dream and interviews explain the human/science-access story, but PubMed/PMC trials and independent replication determine medical evidence. |
| NeuroEPO has a broader past/present science trail beyond Alzheimer’s. | Supported with evidence-level labels. | Animal Alzheimer’s work, healthy-volunteer safety, Parkinson’s/TBI exploratory work, ATHENEA RCT and new trial registrations exist; each sits at a different evidence level. |

| The treatment has a clearly published all-in public price. | Not verified. | I found a US$1,000 coordinator/support package price on NeuralCIM Medical Tourism, but not a public all-in drug/clinic/travel/lodging price. Cubamed says program cost must be requested. |
| Patients can simply subscribe online from another country and receive NeuralCIM by mail. | Not verified. | Public access descriptions point to Cuba clinic evaluation/La Pradera access, medical-record review and travel coordination; no verified legal Canadian/U.S. mail-order subscription route found. |
| Treatment requires medical review/supervision rather than casual supplement-style use. | Supported. | NeuralCIM eligibility/process pages require neurologist report, amyloid PET for Alzheimer’s, recent blood work and La Pradera team review; CECMED material describes prescription/medical supervision. |

| NeuralCIM is authorised in Germany/EU for Alzheimer’s. | Not verified. | Searches found Cuban approval/access claims and EU epoetin products for other indications, but no NeuralCIM Alzheimer’s marketing authorisation from EMA/BfArM. |
| A German patient can subscribe online and have NeuralCIM shipped from Cuba. | Not verified / likely not the normal lawful route. | German BMG/Zoll guidance generally bars unauthorised medicines from consumer mail-order import; formal exceptions include traveller personal need and German-pharmacy individual import under §73(3) AMG. |
| A traveller may personally bring medicine into Germany after foreign treatment. | Potentially, within limits. | German BMG/Zoll describe a travel-necessities exception, generally up to three months’ personal supply at recommended dose, excluding counterfeit/prohibited products and subject to stricter rules for narcotics/doping substances. |